(NOVC.DE) Stock Fundamental Analysis

Europe • Frankfurt Stock Exchange • FRA:NOVC • DK0060534915

86.34 EUR
-2.03 (-2.3%)
Last: Sep 19, 2023, 05:26 PM
Fundamental Rating

6

Taking everything into account, NOVC scores 6 out of 10 in our fundamental rating. NOVC was compared to 55 industry peers in the Pharmaceuticals industry. While NOVC belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. NOVC is not priced too expensively while it is growing strongly. Keep and eye on this one! These ratings could make NOVC a good candidate for growth investing.


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

  • In the past year NOVC was profitable.
  • NOVC had a positive operating cash flow in the past year.
NOVC.DE Yearly Net Income VS EBIT VS OCF VS FCFNOVC.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 20B 40B 60B

1.2 Ratios

  • Looking at the Return On Assets, with a value of 23.95%, NOVC belongs to the top of the industry, outperforming 95.56% of the companies in the same industry.
  • NOVC has a better Return On Equity (74.32%) than 95.56% of its industry peers.
  • NOVC has a better Return On Invested Capital (55.96%) than 97.78% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for NOVC is significantly above the industry average of 14.23%.
  • The last Return On Invested Capital (55.96%) for NOVC is above the 3 year average (49.65%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 23.95%
ROE 74.32%
ROIC 55.96%
ROA(3y)25.55%
ROA(5y)28.51%
ROE(3y)66.85%
ROE(5y)68.54%
ROIC(3y)49.65%
ROIC(5y)55.99%
NOVC.DE Yearly ROA, ROE, ROICNOVC.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 20 40 60 80

1.3 Margins

  • NOVC's Profit Margin of 33.40% is amongst the best of the industry. NOVC outperforms 91.11% of its industry peers.
  • NOVC's Profit Margin has declined in the last couple of years.
  • Looking at the Operating Margin, with a value of 42.80%, NOVC belongs to the top of the industry, outperforming 95.56% of the companies in the same industry.
  • NOVC's Operating Margin has been stable in the last couple of years.
  • NOVC has a better Gross Margin (84.35%) than 84.44% of its industry peers.
  • In the last couple of years the Gross Margin of NOVC has remained more or less at the same level.
Industry RankSector Rank
OM 42.8%
PM (TTM) 33.4%
GM 84.35%
OM growth 3Y-0.97%
OM growth 5Y-0.64%
PM growth 3Y-0.57%
PM growth 5Y-1.67%
GM growth 3Y-0.02%
GM growth 5Y-0.07%
NOVC.DE Yearly Profit, Operating, Gross MarginsNOVC.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 20 40 60 80

6

2. Health

2.1 Basic Checks

  • NOVC has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
  • The number of shares outstanding for NOVC has been reduced compared to 1 year ago.
  • The debt/assets ratio for NOVC has been reduced compared to a year ago.
NOVC.DE Yearly Shares OutstandingNOVC.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 1B 2B 3B 4B
NOVC.DE Yearly Total Debt VS Total AssetsNOVC.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 50B 100B 150B 200B

2.2 Solvency

  • NOVC has an Altman-Z score of 11.18. This indicates that NOVC is financially healthy and has little risk of bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 11.18, NOVC belongs to the top of the industry, outperforming 93.33% of the companies in the same industry.
  • NOVC has a debt to FCF ratio of 0.38. This is a very positive value and a sign of high solvency as it would only need 0.38 years to pay back of all of its debts.
  • The Debt to FCF ratio of NOVC (0.38) is better than 91.11% of its industry peers.
  • NOVC has a Debt/Equity ratio of 0.21. This is a healthy value indicating a solid balance between debt and equity.
  • NOVC has a Debt to Equity ratio (0.21) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.21
Debt/FCF 0.38
Altman-Z 11.18
ROIC/WACC7.69
WACC7.28%
NOVC.DE Yearly LT Debt VS Equity VS FCFNOVC.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 20B 40B 60B 80B

2.3 Liquidity

  • NOVC has a Current Ratio of 0.88. This is a bad value and indicates that NOVC is not financially healthy enough and could expect problems in meeting its short term obligations.
  • The Current ratio of NOVC (0.88) is worse than 84.44% of its industry peers.
  • NOVC has a Quick Ratio of 0.88. This is a bad value and indicates that NOVC is not financially healthy enough and could expect problems in meeting its short term obligations.
  • NOVC's Quick ratio of 0.70 is on the low side compared to the rest of the industry. NOVC is outperformed by 82.22% of its industry peers.
Industry RankSector Rank
Current Ratio 0.88
Quick Ratio 0.7
NOVC.DE Yearly Current Assets VS Current LiabilitesNOVC.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 20B 40B 60B 80B 100B

7

3. Growth

3.1 Past

  • NOVC shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -32.68%.
  • NOVC shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 3.48% yearly.
  • The Revenue has grown by 28.03% in the past year. This is a very strong growth!
  • The Revenue has been growing by 9.64% on average over the past years. This is quite good.
EPS 1Y (TTM)-32.68%
EPS 3Y3.69%
EPS 5Y3.48%
EPS Q2Q%-26.37%
Revenue 1Y (TTM)28.03%
Revenue growth 3Y13.19%
Revenue growth 5Y9.64%
Sales Q2Q%31.59%

3.2 Future

  • NOVC is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.79% yearly.
  • Based on estimates for the next years, NOVC will show a quite strong growth in Revenue. The Revenue will grow by 13.65% on average per year.
EPS Next Y96.77%
EPS Next 2Y52.67%
EPS Next 3Y40.31%
EPS Next 5Y25.79%
Revenue Next Year27.56%
Revenue Next 2Y22.92%
Revenue Next 3Y20.4%
Revenue Next 5Y13.65%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
NOVC.DE Yearly Revenue VS EstimatesNOVC.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100B 200B 300B 400B
NOVC.DE Yearly EPS VS EstimatesNOVC.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 20 40 60 80

4

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 43.17, NOVC can be considered very expensive at the moment.
  • Based on the Price/Earnings ratio, NOVC is valued a bit more expensive than the industry average as 64.44% of the companies are valued more cheaply.
  • Compared to an average S&P500 Price/Earnings ratio of 28.25, NOVC is valued quite expensively.
  • A Price/Forward Earnings ratio of 15.13 indicates a correct valuation of NOVC.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of NOVC indicates a somewhat cheap valuation: NOVC is cheaper than 64.44% of the companies listed in the same industry.
  • NOVC's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.50.
Industry RankSector Rank
PE 43.17
Fwd PE 15.13
NOVC.DE Price Earnings VS Forward Price EarningsNOVC.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • NOVC's Enterprise Value to EBITDA ratio is a bit more expensive when compared to the industry. NOVC is more expensive than 64.44% of the companies in the same industry.
  • The rest of the industry has a similar Price/Free Cash Flow ratio as NOVC.
Industry RankSector Rank
P/FCF 42.68
EV/EBITDA 30.33
NOVC.DE Per share dataNOVC.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The decent profitability rating of NOVC may justify a higher PE ratio.
  • NOVC's earnings are expected to grow with 40.31% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.45
PEG (5Y)12.41
EPS Next 2Y52.67%
EPS Next 3Y40.31%

0

5. Dividend

5.1 Amount

  • NOVC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

FRA:NOVC (9/19/2023, 5:26:42 PM)

86.34

-2.03 (-2.3%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)N/A
Earnings (Next)N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap386.28B
Revenue(TTM)201.32B
Net Income(TTM)67.24B
Analysts70.63
Price Target169.94 (96.83%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP41.57%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.26%
Min EPS beat(2)-6.63%
Max EPS beat(2)2.11%
EPS beat(4)3
Avg EPS beat(4)-0.09%
Min EPS beat(4)-6.63%
Max EPS beat(4)2.85%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)99180.3%
Min Revenue beat(2)97265.9%
Max Revenue beat(2)101095%
Revenue beat(4)4
Avg Revenue beat(4)100079%
Min Revenue beat(4)97265.9%
Max Revenue beat(4)101151%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)4.68%
PT rev (3m)6.75%
EPS NQ rev (1m)-50.34%
EPS NQ rev (3m)-49.42%
EPS NY rev (1m)0.22%
EPS NY rev (3m)4.6%
Revenue NQ rev (1m)-99.9%
Revenue NQ rev (3m)-99.9%
Revenue NY rev (1m)0.24%
Revenue NY rev (3m)3.71%
Valuation
Industry RankSector Rank
PE 43.17
Fwd PE 15.13
P/S 14.31
P/FCF 42.68
P/OCF 32.1
P/B 31.84
P/tB 72.51
EV/EBITDA 30.33
EPS(TTM)2
EY2.32%
EPS(NY)5.71
Fwd EY6.61%
FCF(TTM)2.02
FCFY2.34%
OCF(TTM)2.69
OCFY3.12%
SpS6.03
BVpS2.71
TBVpS1.19
PEG (NY)0.45
PEG (5Y)12.41
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 23.95%
ROE 74.32%
ROCE 69.41%
ROIC 55.96%
ROICexc 79.18%
ROICexgc 187.85%
OM 42.8%
PM (TTM) 33.4%
GM 84.35%
FCFM 33.53%
ROA(3y)25.55%
ROA(5y)28.51%
ROE(3y)66.85%
ROE(5y)68.54%
ROIC(3y)49.65%
ROIC(5y)55.99%
ROICexc(3y)59.43%
ROICexc(5y)70.56%
ROICexgc(3y)107.14%
ROICexgc(5y)103.87%
ROCE(3y)66.16%
ROCE(5y)72.5%
ROICexgc growth 3Y12.28%
ROICexgc growth 5Y2.92%
ROICexc growth 3Y-8.96%
ROICexc growth 5Y-9.74%
OM growth 3Y-0.97%
OM growth 5Y-0.64%
PM growth 3Y-0.57%
PM growth 5Y-1.67%
GM growth 3Y-0.02%
GM growth 5Y-0.07%
F-Score7
Asset Turnover0.72
Health
Industry RankSector Rank
Debt/Equity 0.21
Debt/FCF 0.38
Debt/EBITDA 0.21
Cap/Depr 278.9%
Cap/Sales 11.04%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality 100.38%
Current Ratio 0.88
Quick Ratio 0.7
Altman-Z 11.18
F-Score7
WACC7.28%
ROIC/WACC7.69
Cap/Depr(3y)235.6%
Cap/Depr(5y)244.27%
Cap/Sales(3y)10.33%
Cap/Sales(5y)10.26%
Profit Quality(3y)95.36%
Profit Quality(5y)92.36%
High Growth Momentum
Growth
EPS 1Y (TTM)-32.68%
EPS 3Y3.69%
EPS 5Y3.48%
EPS Q2Q%-26.37%
EPS Next Y96.77%
EPS Next 2Y52.67%
EPS Next 3Y40.31%
EPS Next 5Y25.79%
Revenue 1Y (TTM)28.03%
Revenue growth 3Y13.19%
Revenue growth 5Y9.64%
Sales Q2Q%31.59%
Revenue Next Year27.56%
Revenue Next 2Y22.92%
Revenue Next 3Y20.4%
Revenue Next 5Y13.65%
EBIT growth 1Y29.73%
EBIT growth 3Y12.1%
EBIT growth 5Y8.94%
EBIT Next Year38.11%
EBIT Next 3Y23.19%
EBIT Next 5Y17.5%
FCF growth 1Y112.16%
FCF growth 3Y21.73%
FCF growth 5Y14.55%
OCF growth 1Y65.59%
OCF growth 3Y19.03%
OCF growth 5Y13.89%

/ NOVC.DE FAQ

What is the fundamental rating for NOVC stock?

ChartMill assigns a fundamental rating of 7 / 10 to NOVC.DE.


What is the valuation status of (NOVC.DE) stock?

ChartMill assigns a valuation rating of 4 / 10 to (NOVC.DE). This can be considered as Fairly Valued.


How profitable is (NOVC.DE) stock?

(NOVC.DE) has a profitability rating of 9 / 10.


What is the financial health of (NOVC.DE) stock?

The financial health rating of (NOVC.DE) is 7 / 10.


How sustainable is the dividend of (NOVC.DE) stock?

The dividend rating of (NOVC.DE) is 4 / 10 and the dividend payout ratio is 41.57%.